Publications
FLCRM: Functional linear cox regression model." Biometrics 74, no. 1 (2018): 109-117.
"A simple and accurate method to determine genomewide significance for association tests in sequencing studies." Genet Epidemiol 43, no. 4 (2019): 365-372.
"Identifying individual risk rare variants using protein structure guided local tests (POINT)." PLoS Comput Biol 15, no. 2 (2019): e1006722.
"Rapid enrollment design for finding the optimal dose in immunotherapy trials with ordered groups." J Biopharm Stat 29, no. 4 (2019): 625-634.
"Multivariate varying coefficient models for DTI tract statistics." Med Image Comput Comput Assist Interv 13, no. Pt 1 (2010): 690-7.
"Statistical significance for hierarchical clustering." Biometrics 73, no. 3 (2017): 811-821.
"Rare Variants Association Analysis in Large-Scale Sequencing Studies at the Single Locus Level." PLoS Comput Biol 12, no. 6 (2016): e1004993.
"Testing and estimation in marker-set association study using semiparametric quantile regression kernel machine." Biometrics 72, no. 2 (2016): 364-71.
"A multiple imputation strategy for sequential multiple assignment randomized trials." Stat Med 33, no. 24 (2014): 4202-14.
"Functional-mixed effects models for candidate genetic mapping in imaging genetic studies." Genet Epidemiol 38, no. 8 (2014): 680-91.
"Semiparametric inference for a 2-stage outcome-auxiliary-dependent sampling design with continuous outcome." Biostatistics 12, no. 3 (2011): 521-34.
"Comparing oncology clinical programs by use of innovative designs and expected net present value optimization: Which adaptive approach leads to the best result?" J Biopharm Stat 27, no. 3 (2017): 457-476.
"Empirical pathway analysis, without permutation." Biostatistics 14, no. 3 (2013): 573-85.
"Prediction of cancer drug sensitivity using high-dimensional omic features." Biostatistics 18, no. 1 (2017): 1-14.
"Bayesian design of a survival trial with a cured fraction using historical data." Stat Med 37, no. 26 (2018): 3814-3831.
"Bayesian path specific frailty models for multi-state survival data with applications." Biometrics 71, no. 3 (2015): 760-71.
"Accelerated failure time model for data from outcome-dependent sampling." Lifetime Data Anal 27, no. 1 (2021): 15-37.
"TEAM: efficient two-locus epistasis tests in human genome-wide association study." Bioinformatics 26, no. 12 (2010): i217-27.
"A New Method for Detecting Associations with Rare Copy-Number Variants." PLoS Genet 11, no. 10 (2015): e1005403.
"Analysing breast cancer microarrays from African Americans using shrinkage-based discriminant analysis." Hum Genomics 5, no. 1 (2010): 5-16.
"Integrative gene set analysis of multi-platform data with sample heterogeneity." Bioinformatics 30, no. 11 (2014): 1501-7.
"SCOPE: A Normalization and Copy-Number Estimation Method for Single-Cell DNA Sequencing." Cell Syst 10, no. 5 (2020): 445-452.e6.
"Application of a sequential multiple assignment randomized trial (SMART) design in older patients with chronic lymphocytic leukemia." Ann Oncol 30, no. 4 (2019): 542-550.
"Efficient semiparametric estimation of short-term and long-term hazard ratios with right-censored data." Biometrics 69, no. 4 (2013): 840-9.
"A framework for transcriptome-wide association studies in breast cancer in diverse study populations." Genome Biol 21, no. 1 (2020): 42.
"A junction coverage compatibility score to quantify the reliability of transcript abundance estimates and annotation catalogs." Life Sci Alliance 2, no. 1 (2019).
"Studying gene and gene-environment effects of uncommon and common variants on continuous traits: a marker-set approach using gene-trait similarity regression." Am J Hum Genet 89, no. 2 (2011): 277-88.
"Recent progresses in outcome-dependent sampling with failure time data." Lifetime Data Anal 23, no. 1 (2017): 57-82.
"Analysis of untyped SNPs: maximum likelihood and imputation methods." Genet Epidemiol 34, no. 8 (2010): 803-15.
"A practical Bayesian adaptive design incorporating data from historical controls." Stat Med 37, no. 27 (2018): 4054-4070.
"Provider-based research networks and diffusion of surgical technologies among patients with early-stage kidney cancer." Cancer 121, no. 6 (2015): 836-43.
"Single-nucleotide resolution analysis of nucleotide excision repair of ribosomal DNA in humans and mice." J Biol Chem 294, no. 1 (2019): 210-217.
"Joint skeleton estimation of multiple directed acyclic graphs for heterogeneous population." Biometrics 75, no. 1 (2019): 36-47.
"Global copy number profiling of cancer genomes." Bioinformatics 32, no. 6 (2016): 926-8.
"Statistical methods for multivariate meta-analysis of diagnostic tests: An overview and tutorial." Stat Methods Med Res 25, no. 4 (2016): 1596-619.
"Receiver operating characteristic curves and confidence bands for support vector machines." Biometrics 77, no. 4 (2021): 1422-1430.
"On variance estimate for covariate adjustment by propensity score analysis." Stat Med 35, no. 20 (2016): 3537-48.
"The rapid enrollment design for Phase I clinical trials." Stat Med 35, no. 15 (2016): 2516-24.
"A general framework for detecting disease associations with rare variants in sequencing studies." Am J Hum Genet 89, no. 3 (2011): 354-67.
"Sufficient dimension reduction via bayesian mixture modeling." Biometrics 67, no. 3 (2011): 886-95.
"Medical records-based postmarketing safety evaluation of rare events with uncertain status." J Biopharm Stat 23, no. 1 (2013): 201-12.
"Semiparametric estimation of the accelerated failure time model with partly interval-censored data." Biometrics 73, no. 4 (2017): 1161-1168.
"Evaluating haplotype effects in case-control studies via penalized-likelihood approaches: prospective or retrospective analysis?" Genet Epidemiol 34, no. 8 (2010): 892-911.
"Basic concepts and methods for joint models of longitudinal and survival data." J Clin Oncol 28, no. 16 (2010): 2796-801.
"Power and sample size calculation for microarray studies." J Biopharm Stat 22, no. 1 (2012): 30-42.
"Bayesian meta-experimental design: evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes." Biometrics 68, no. 2 (2012): 578-86.
"Estimation of treatment effect for the sequential parallel design." Stat Med 30, no. 30 (2011): 3496-506.
"Multiple testing for gene sets from microarray experiments." BMC Bioinformatics 12 (2011): 209.
"Ascertainment, classification, and impact of neoplasm detection during prolonged treatment with dual antiplatelet therapy with prasugrel vs. clopidogrel following acute coronary syndrome." Eur Heart J 37, no. 4 (2016): 412-22.
"Using decision lists to construct interpretable and parsimonious treatment regimes." Biometrics 71, no. 4 (2015): 895-904.
"Improved doubly robust estimation when data are monotonely coarsened, with application to longitudinal studies with dropout." Biometrics 67, no. 2 (2011): 536-45.
"Optimal estimation for regression models on τ-year survival probability." J Biopharm Stat 25, no. 3 (2015): 539-47.
"Efficient estimation of grouped survival models." BMC Bioinformatics 20, no. 1 (2019): 269.
"Multivariate network-level approach to detect interactions between large-scale functional systems." Med Image Comput Comput Assist Interv 13, no. Pt 2 (2010): 298-305.
"Randomized, double-blind study comparing proposed biosimilar LA-EP2006 with reference pegfilgrastim in breast cancer." Future Oncol 12, no. 11 (2016): 1359-67.
"Bayesian longitudinal low-rank regression models for imaging genetic data from longitudinal studies." Neuroimage 149 (2017): 305-322.
"Genetic association analysis under complex survey sampling: the Hispanic Community Health Study/Study of Latinos." Am J Hum Genet 95, no. 6 (2014): 675-88.
"Radiomics analysis using stability selection supervised component analysis for right-censored survival data." Comput Biol Med 124 (2020): 103959.
"Greedy outcome weighted tree learning of optimal personalized treatment rules." Biometrics 73, no. 2 (2017): 391-400.
"Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR, HER2 breast cancer that had progressed during or after prior endocrine therapy." Breast Cancer Res 19, no. 1 (2017): 18.
"Estimating individualized treatment rules for ordinal treatments." Biometrics 74, no. 3 (2018): 924-933.
"A longitudinal functional analysis framework for analysis of white matter tract statistics." Inf Process Med Imaging 23 (2013): 220-31.
"Independence screening for high dimensional nonlinear additive ODE models with applications to dynamic gene regulatory networks." Stat Med 37, no. 17 (2018): 2630-2644.
"Diseased region detection of longitudinal knee MRI data." Inf Process Med Imaging 23 (2013): 632-43.
"Optimal two-stage log-rank test for randomized phase II clinical trials." J Biopharm Stat 27, no. 4 (2017): 639-658.
"Nucleotide excision repair capacity increases during differentiation of human embryonic carcinoma cells into neurons and muscle cells." J Biol Chem 294, no. 15 (2019): 5914-5922.
"Robust regression for optimal individualized treatment rules." Stat Med 38, no. 11 (2019): 2059-2073.
"Sparse meta-analysis with high-dimensional data." Biostatistics 17, no. 2 (2016): 205-20.
"Enrollment Trends and Disparity Among Patients With Lung Cancer in National Clinical Trials, 1990 to 2012." J Clin Oncol 34, no. 33 (2016): 3992-3999.
"Response to reader reaction." Biometrics 71, no. 1 (2015): 267-273.
"Proportional exponentiated link transformed hazards (ELTH) models for discrete time survival data with application." Lifetime Data Anal 22, no. 1 (2016): 38-62.
"Latent class model characterization of neighborhood socioeconomic status." Cancer Causes Control 27, no. 3 (2016): 445-52.
"Validation of Progression-Free Survival as a Surrogate Endpoint for Overall Survival in Malignant Mesothelioma: Analysis of Cancer and Leukemia Group B and North Central Cancer Treatment Group (Alliance) Trials." Oncologist 22, no. 2 (2017): 189-198.
"Bayesian sequential meta-analysis design in evaluating cardiovascular risk in a new antidiabetic drug development program." Stat Med 33, no. 9 (2014): 1600-18.
"I-Boost: an integrative boosting approach for predicting survival time with multiple genomics platforms." Genome Biol 20, no. 1 (2019): 52.
"Bayesian probability of success for clinical trials using historical data." Stat Med 34, no. 2 (2015): 249-64.
"The analysis of multivariate longitudinal data: a review." Stat Methods Med Res 23, no. 1 (2014): 42-59.
"Analysis of multiple survival events in generalized case-cohort designs." Biometrics 74, no. 4 (2018): 1250-1260.
"SNPpy--database management for SNP data from genome wide association studies." PLoS One 6, no. 10 (2011): e24982.
"Pharmacogenomics as a risk mitigation strategy for chemotherapeutic cardiotoxicity." Pharmacogenomics 14, no. 2 (2013): 205-13.
"FMEM: functional mixed effects modeling for the analysis of longitudinal white matter Tract data." Neuroimage 84 (2014): 753-64.
"SMAC: Spatial multi-category angle-based classifier for high-dimensional neuroimaging data." Neuroimage 175 (2018): 230-245.
"A genome-wide association study identifies novel loci for paclitaxel-induced sensory peripheral neuropathy in CALGB 40101." Clin Cancer Res 18, no. 18 (2012): 5099-109.
"Semiparametric Bayesian local functional models for diffusion tensor tract statistics." Neuroimage 63, no. 1 (2012): 460-74.
"Modelling recurrent events: a tutorial for analysis in epidemiology." Int J Epidemiol 44, no. 1 (2015): 324-33.
"Statistical Considerations for Subgroup Analyses." J Thorac Oncol 16, no. 3 (2021): 375-380.
"A regularized variable selection procedure in additive hazards model with stratified case-cohort design." Lifetime Data Anal 24, no. 3 (2018): 443-463.
"Estimating effect of environmental contaminants on women's subfecundity for the MoBa study data with an outcome-dependent sampling scheme." Biostatistics 15, no. 4 (2014): 636-50.
"Variable selection for optimal treatment decision." Stat Methods Med Res 22, no. 5 (2013): 493-504.
"Static and Dynamic DNA Loops form AP-1-Bound Activation Hubs during Macrophage Development." Mol Cell 67, no. 6 (2017): 1037-1048.e6.
"Predicting risk of chemotherapy-induced severe neutropenia: A pooled analysis in individual patients data with advanced lung cancer." Lung Cancer 141 (2020): 14-20.
"Inference on treatment effects from a randomized clinical trial in the presence of premature treatment discontinuation: the SYNERGY trial." Biostatistics 12, no. 2 (2011): 258-69.
"Bayesian modeling and inference for clinical trials with partial retrieved data following dropout." Stat Med 32, no. 24 (2013): 4180-95.
"K-Sample comparisons using propensity analysis." Biom J 61, no. 3 (2019): 698-713.
"Fixed and random effects selection in mixed effects models." Biometrics 67, no. 2 (2011): 495-503.
"Bayesian inference for multivariate meta-analysis Box-Cox transformation models for individual patient data with applications to evaluation of cholesterol-lowering drugs." Stat Med 32, no. 23 (2013): 3972-90.
"Sample size determination in shared frailty models for multivariate time-to-event data." J Biopharm Stat 24, no. 4 (2014): 908-23.
"Superiority of combining two independent trials in interim futility analysis." Stat Methods Med Res 29, no. 2 (2020): 522-540.
"Reporting and Guidelines in Propensity Score Analysis: A Systematic Review of Cancer and Cancer Surgical Studies." J Natl Cancer Inst 109, no. 8 (2017).
"Translational studies of phenotypic probes for the mononuclear phagocyte system and liposomal pharmacology." J Pharmacol Exp Ther 347, no. 3 (2013): 599-606.
"